



Genflow CEO to participate in distinguished panel in the United States

London, 16 May 2022: Genflow Biosciences (LSE: GENF) is pleased to announce that its founder and CEO, Dr Eric Leire, has been selected to take part in a distinguished panel in the United States to discuss Belgium's role in nurturing the development of next-generation therapeutics.

The one-day event entitled "How Belgium fosters the development of Next-Generation Therapeutics" is being held today, May 16th in Washington DC and will be hosted by the Belgian government; the Belgian ambassador to the US and government agency Flanders Investment and Trade. The event coincides with the 25th Annual meeting of the American Society of Gene and Cell Therapy.

Dr Leire will discuss the science underlying Genflow's approach to longevity and the impact this exciting field will have on the future of cell and gene therapies, in addition to the opportunities that lie ahead given the longevity sector has emerged as a major business and research area within life sciences and biotechnology.

Dr Leire joins a distinguished panel of speakers from both sides of the Atlantic focused on the topic of cell and gene therapy including Prof. Dr. Kevin Braeckmans from the Laboratory of General Biochemistry and Physical Pharmacy at Ghent University; Korneel Grauwet from Harvard Medical School; Prof. Els Henckaerts, from the Department of Cellular and Molecular Medicine and the Department of Microbiology, Immunology and Transplantation at Katholieke Universiteit Leuven; and Luk Vandenberghe, Associate Professor at Harvard Medical School and Associate Member of the Broad Institute of Harvard and MIT in Boston.

Genflow is a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age. It is the first longevity biotechnology company to list in Europe and seeks to be a reference company in the European longevity sector.

Dr Eric Leire, Founder and CEO of Genflow, said: "I am delighted to participate in this event which is centred on the vital issue of how to best foster the development of the next generation of therapeutics that we will all come to rely on. This is a great initiative by the Belgian government and it is an honour to join this esteemed panel. I look forward to speaking about the opportunities for the longevity sector and discussing the gene therapies of tomorrow."

Media contacts

Tancredi Intelligent Communication

genflowbio@tancredigroup.com

Salamander Davoudi

M: +44 (0) 7957 549 906

salamander@tancredigroup.com

Helen Humphrey

M: +44 (0) 7449 226720

helen@tancredigroup.com

Benedetta Negri da Oleggio

M: +44 (0) 7838 029 970

benedetta@tancredigroup.com



About Genflow Biosciences

Genflow Biosciences is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno associated virus (“AAV”) vectors to deliver copies of the Sirtuin-6 (“SIRT6”) gene variant that is found in centenarians into cells.

Its mission is to increase understanding of the factors that control and impact lifespan. Genflow researches, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com